MYC in renal cell carcinoma: pathogenic mechanisms and pharmacological intervention strategies.
文献摘要
As a pleiotropic master transcriptional regulator that controls an extensive, context-dependent repertoire of target genes governing cell-fate determination, the oncoprotein c-Myc has long been regarded as an "undruggable" therapeutic target. In renal cell carcinoma (RCC), aberrant c‑Myc activation serves as a critical driver of tumor progression and therapeutic resistance, rendering it a high‑priority yet therapeutically intractable target for pharmacological intervention. To systematically delineate the research landscape and translational potential of c‑Myc in RCC, this review summarizes current advances from multiple dimensions. The structural features and physiological functions of c-Myc are first introduced, after which the role of dysregulated c-Myc signaling in mediating key malignant phenotypes of RCC, including excessive proliferation, metastasis, immune escape, and therapeutic resistance, is comprehensively summarized. Subsequently, mainstream pharmacological strategies targeting MYC signaling are reviewed, with emphasis on their molecular mechanisms, therapeutic rationale, and prospects for clinical translation. Furthermore, natural bioactive compounds and traditional Chinese medicine formulas with the potential to modulate MYC signaling in RCC are systematically categorized, with emphasis on their regulatory mechanisms, including MYC transcriptional inhibition, c-Myc protein destabilization, remodeling of downstream oncogenic transcriptional networks, and translational potential. This review integrates updated pathogenic mechanisms and pharmacological advances, providing a concise theoretical basis for developing c‑Myc-targeted innovative drugs against RCC.